PSTV — Plus Therapeutics Cashflow Statement
0.000.00%
- $61.54m
- $54.67m
- $5.82m
Annual cashflow statement for Plus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.24 | -13.4 | -20.3 | -13.3 | -13 |
| Depreciation | |||||
| Non-Cash Items | -0.678 | 1.49 | 1.09 | 0.953 | -1.52 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.119 | 1.24 | 5.6 | -1.12 | 3.22 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -8.43 | -10.3 | -13 | -12.9 | -10.6 |
| Capital Expenditures | -0.493 | -0.144 | -0.509 | -0.16 | -0.691 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | 0.062 | -0.25 | 0 | -3.42 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.493 | -0.082 | -0.759 | -0.16 | -4.11 |
| Financing Cash Flow Items | — | — | — | -0.348 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.319 | 20.4 | 13.5 | 3.44 | 6.19 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.25 | 10.1 | -0.28 | -9.57 | -8.48 |